Visar resultat 1 - 5 av 120 avhandlingar innehållade ordet glioblastoma.
Sammanfattning : Glioblastoma (GBM) is the most common high-grade brain tumor diagnosed in patients who are more than 50 years of age. The standard of care treatment is surgery, followed by radiotherapy and chemotherapy. The median life expectancy of patients is only between 12 to 15 months after receiving current treatment regimes. LÄS MER
Sammanfattning : One of the major problems with malignant brain tumours, such as glioblastoma multiforme, is that despite being able to remove the major bulk of the tumour through surgery and treating the patients with chemotherapy and radiotherapy, we know that tumour cells have already spread throughout the brain. Furthermore, we now know that the glioblastoma cells effectively suppress the patients’ own anti-tumour response. LÄS MER
Sammanfattning : Human glioblastoma is a primary brain tumour with a bad prognosis. One major contributing factor is that the tumour grows in an infiltrative way. Single tumour cells, undetectable with today's techniques, invade the brain and escape therapy. LÄS MER
4. Large scale integration and interactive exploration of cancer data – with applications to glioblastoma
Sammanfattning : Glioblastoma is the most common malignant brain tumor, with a median survival of approximately 15 months. The standard of care treatment consists of surgical resection followed by radiotherapy and chemotherapy, where chemotherapy only prolongs survival by approximately 3 months. LÄS MER
Sammanfattning : Crossing the blood-brain barrier (BBB) is a great challenge for delivery of highly charged macromolecules such as nucleic acids and proteins to the brain. Cell-penetrating peptides (CPPs) are promising vectors to deliver various cargoes ranging from small molecules to large molecules such as antibodies, proteins, and nucleic acids. LÄS MER